循环肿瘤DNA测序用于霍奇金淋巴瘤患者的生物学分类与个体化风险分层
研究对243例德国霍奇金研究组试验患者行循环肿瘤DNA测序,提出霍奇金淋巴瘤三种生物学亚型,并在96例EuroNet-PHL-C2研究患者中独立验证;在72例HD21试验富集队列中用优化检测显示亚型间无进展生存期显著差异,微小残留病检测可识别亚型内极高复发风险患者。
要点
- 循环肿瘤DNA测序可将霍奇金淋巴瘤分为炎症免疫逃逸型、病毒驱动型和致癌基因驱动型三种生物学亚型。
- 优化且验证的检测版本显示三种亚型间无进展生存期存在显著差异。
- 微小残留病评估可识别各亚型内复发风险极高的患者。
核心结论
- 作者提出一种基于循环肿瘤DNA测序的临床可行、非侵入性方法,用于霍奇金淋巴瘤患者的个体化风险分层和微小残留病监测。
研究设计与样本
- 研究对来自德国霍奇金研究组关键试验的243例患者行循环肿瘤DNA测序以识别霍奇金淋巴瘤亚型。
- 在EuroNet-PHL-C2研究中治疗的96例患者中对亚型进行独立验证。
- 在包含HD21试验72例患者的富集临床验证队列中,使用优化、验证且临床可行的检测评估亚型间的结局差异。
主要发现
- 炎症免疫逃逸型霍奇金淋巴瘤以频繁拷贝数变异为特征,包括PD-L1位点高水平扩增等免疫逃逸变异,以及炎症性肿瘤微环境。
- 病毒驱动型霍奇金淋巴瘤与EB病毒和/或人类疱疹病毒6型相关,肿瘤微环境为炎症性、含中性粒细胞和巨噬细胞,而肿瘤突变负荷低。
- 致癌基因驱动型霍奇金淋巴瘤以高肿瘤突变负荷、TNFAIP3、ITPKB和SOCS1等致癌驱动基因反复突变为特征,肿瘤微环境为冷肿瘤。
- 优化且验证的检测版本显示三种亚型间无进展生存期存在显著差异。
- 微小残留病评估可检测各亚型内复发风险极高的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Current clinical challenges in Hodgkin lymphoma (HL) include difficult-to-treat relapsed/refractory disease and considerable long-term toxicities of treatment. Since clinical risk factors lack discriminatory power, intensity of therapy is mainly based on tumor burden. Exploring HL genetics and tumor microenvironment (TME) might provide valuable insights for improved risk stratification. MATERIALS AND METHODS: In this study, we applied circulating tumor DNA sequencing to 243 patients obtained from pivotal German Hodgkin Study Group trials to identify subtypes of HL. Independent validation of the subtypes was performed in 96 patients treated in the EuroNet-PHL-C2 study. Outcome differences of subtypes were assessed in an event-enriched clinical validation cohort comprising 72 patients from the HD21 trial, using a refined, validated, and clinically feasible assay. RESULTS: We propose a biologic classification of HL consisting of three distinct subtypes: inflammatory immune escape HL is characterized by frequent copy-number variations including immune escape variants such as high-level amplifications of the PD-L1 locus and an inflammatory TME. Virally-driven HL is associated with Epstein-Barr virus and/or human herpesvirus 6 and an inflammatory TME with neutrophils and macrophages, while the tumor mutational burden (TMB) is low. Oncogene-driven HL is defined by a high TMB, recurrent mutations in oncogenic drivers such as TNFAIP3, ITPKB, and SOCS1, and a cold TME. A refined and validated assay version aiming at clinically feasible risk stratification showed significant progression-free survival differences between subtypes. In addition, assessment of minimal residual disease (MRD) allowed for the detection of patients at very high risk of relapse within the subtypes. CONCLUSION: We propose a clinically feasible, noninvasive method for individualized risk stratification and MRD monitoring in patients with HL on the basis of circulating tumor DNA sequencing.
引用
- Heger JM, Mammadova L, Mattlener J, et al. Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma. J Clin Oncol. 2024. PMID: 39348625. doi:10.1200/JCO.23.01867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。